L07

Ancillary Materials Manufacturing, Biosafety, and Performance

Allen B. Parsons  |  Akron Bio
Andrew Schaefer and John Brabazon  |  Eurofins BioPharma Product Testing

Learning Goal

Describe manufacturing practices, quality systems, and biosafety considerations associated with ancillary materials, and explain how ancillary materials are evaluated and qualified for performance in specific applications.

Learning Objectives

After this lesson you will be able to:

  • Identify QMS elements affecting ancillary materials
  • Explain manufacturing controls that influence contamination risk
  • Describe traceability requirements for biological materials
  • Explain safety testing requirements
  • Describe qualification strategies
  • Explain qualification of ancillary materials for intended use
  • Explain how performance assays are designed and interpreted
  • Evaluate supplier and user generated performance data
Slides: pages 231 to 287 of the student packet
Knowledge Check: below the videos (ungraded)

Watch

Three videos, in order: Allen B. Parsons, then Eurofins Part 1, then Eurofins Part 2.

Knowledge Check

Ungraded. Answer each question, then open the answer to check your work.

Q37. A quality manager says: 'Our QMS prevents manufacturing errors from happening.' Allen would correct this statement. How?

  1. Allen would say a QMS does not prevent all errors but ensures that when nonconformities occur, an organized and effective corrective action strategy is in place to identify root causes and correct them in a timely manner
  2. Allen would agree - a well-designed QMS does prevent manufacturing errors
  3. Allen would say QMS only applies to the final product, not to ancillary material manufacturing
  4. Allen would agree that a QMS with ISO 9001 certification prevents all manufacturing errors
Show answer

A) Allen would say a QMS does not prevent all errors but ensures that when nonconformities occur, an organized and effective corrective action strategy is in place to identify root causes and correct them in a timely manner

Rationale: Allen explains: 'Things do not always go as planned. When nonconformities are recognized, there needs to be an organized and effective strategy to ensure that the root cause is identified and corrected.' The QMS manages errors, it does not prevent them all.

Q38. A supplier claims their ancillary medium is 'animal-derived component free.' What documentation would you require to substantiate this claim under ISO 20399?

  1. A signed letter from the supplier's quality director confirming the claim
  2. A certificate of analysis showing no animal-derived components detected
  3. ISO 9001 certification of the supplier's manufacturing facility
  4. Documentation of both product ingredients AND production history—both must be assessed to support this claim credibly
Show answer

D) Documentation of both product ingredients AND production history—both must be assessed to support this claim credibly

Rationale: Allen specifies that an animal-derived component free claim requires documentation of both product ingredients (what is in the material) and production history (what was used to make it)—examining every input and step.

Q39. Your ancillary material supplier changes their container closure system from glass vials to plastic bags. Beyond checking the material itself, what additional evaluation does ISO 20399 suggest you consider?

  1. No additional evaluation is needed if the ancillary material formula has not changed
  2. A new sterility test only, since container changes primarily affect sterility
  3. An extractables and leachables risk assessment to evaluate whether the new contact material introduces any new leachable risk to the ancillary material and downstream manufacturing process
  4. A full re-qualification of the ancillary material from pre-clinical stage
Show answer

C) An extractables and leachables risk assessment to evaluate whether the new contact material introduces any new leachable risk to the ancillary material and downstream manufacturing process

Rationale: Changes to container closure systems may introduce new leachables. Asif Mahmood reinforces this in his section: when container contact materials change, an E&L risk assessment is needed to evaluate potential impact.

Q40. When irradiation is used to sterilize an ancillary material, what must the supplier confirm and document beyond simply stating the dose applied?

  1. Only the irradiation dose is required - dose documentation is sufficient for regulatory purposes
  2. Both that the irradiation range effectively eliminates pathogens of concern AND that the irradiation process does not damage the ancillary material to the detriment of its quality and performance
  3. That the irradiation was conducted at a government-certified facility only
  4. That the material was retested after irradiation using the same methods as pre-irradiation
Show answer

B) Both that the irradiation range effectively eliminates pathogens of concern AND that the irradiation process does not damage the ancillary material to the detriment of its quality and performance

Rationale: Allen states: 'The range of irradiation should be confirmed to both effectively eliminate pathogens of concern' and that the process does not damage the ancillary material—both aspects must be validated and documented.

Q41. A cell therapy manufacturer asks why they might need to test an ancillary material themselves if the supplier already provides comprehensive safety data. When might additional user-side testing be required?

  1. When the user's specific risk assessment and intended use indicate that additional testing is needed to demonstrate safety to cells and humans in their specific manufacturing context
  2. Never - comprehensive supplier testing always satisfies user-side requirements
  3. Only when the FDA requests it during an IND review
  4. Only for Tier 3 and Tier 4 materials
Show answer

A) When the user's specific risk assessment and intended use indicate that additional testing is needed to demonstrate safety to cells and humans in their specific manufacturing context

Rationale: Allen explains users may need additional testing 'based on risk and use to demonstrate safety to cells and humans'—determined by the user's own assessment of how the material is used in their specific process.

Q42. A supplier's ancillary material is produced using a murine cell line as part of the manufacturing process, but the final product does not contain any murine cells. Does this require traceability documentation?

  1. No - traceability only applies to components that are directly present in the final ancillary material
  2. Only if the murine cell line is of oncogenic origin
  3. No - this only applies to materials of human origin under ISO 20399
  4. Yes - suppliers need to understand the use of animal-derived materials at every level of manufacturing, not only when they are directly present in the final product, and must document and trace those inputs
Show answer

D) Yes - suppliers need to understand the use of animal-derived materials at every level of manufacturing, not only when they are directly present in the final product, and must document and trace those inputs

Rationale: Allen is clear: 'Ancillary material suppliers need to understand the use of animal-derived materials at every level of manufacturing, not only when they are used directly in their ancillary material manufacturing process.'

Q43. A supplier's performance assay shows consistent lot-to-lot results for their cytokine product. The user accepts this data and moves forward without testing the cytokine in their own process. What is missing?

  1. Nothing - the supplier's validated performance data is sufficient for qualification
  2. The user must qualify the ancillary material through use of the product in their specific manufacturing context - supplier data alone does not confirm suitability for the user's specific intended use
  3. The user only needs to confirm the cytokine concentration matches the CoA specification
  4. The user should request the raw data behind the supplier's assay but does not need to run their own tests
Show answer

B) The user must qualify the ancillary material through use of the product in their specific manufacturing context - supplier data alone does not confirm suitability for the user's specific intended use

Rationale: Andrew and John state: 'user should qualify the ancillary material through the use of the product.' Supplier data supports but does not replace user qualification in the context of the user's specific process.

Q44. You are in Phase 1 and your qualification plan for a new growth factor includes only identity and safety testing. A colleague says you need full validation of all assays now. Who is right, according to ISO 20399?

  1. Your colleague - all assay methods must be fully validated regardless of development phase
  2. Your colleague - ISO 20399 does not allow phase-appropriate qualification
  3. You are right - a phase-appropriate approach is recognized: identity and safety are paramount in early phases, with increasing stringency as development progresses toward Phase 3 and commercial
  4. You are right - assay validation is never required for ancillary materials, only for drug substance methods
Show answer

C) You are right - a phase-appropriate approach is recognized: identity and safety are paramount in early phases, with increasing stringency as development progresses toward Phase 3 and commercial

Rationale: Andrew and John describe a phase-appropriate framework: 'when we are in pre-clinical going into phase 2, identity of materials is paramount, certainly safety and any known critical material attributes.' Full qualification builds toward Phase 3 and commercial.

Q45. A performance assay for a cell isolation reagent shows high batch-to-batch variability in the supplier's own data. What should the AM user do with this information?

  1. Use it as risk-ranked input - high variability in a critical material attribute should elevate the qualification requirements and may require tighter specifications or additional controls in the user's process
  2. Ignore it if each lot passes the minimum specification threshold
  3. Request that the supplier re-run the assay until consistent results are achieved
  4. Document the variability and move on - performance variability is expected and acceptable for all ancillary materials
Show answer

A) Use it as risk-ranked input - high variability in a critical material attribute should elevate the qualification requirements and may require tighter specifications or additional controls in the user's process

Rationale: Andrew and John explain that CMAs must be risk-ranked based on their impact on drug product CQAs. High variability in a critical material attribute is precisely the kind of information that should drive qualification strategy decisions.

Q46. When changes are made to an ancillary material mid-development, what does ISO 20399 require the user to evaluate?

  1. Only whether the new lot passes the existing certificate of analysis specifications
  2. Whether the change requires a new supplier audit only
  3. Nothing - changes to ancillary materials are the supplier's responsibility to document
  4. Whether the methods and assays used to characterize and qualify the material remain valid for the changed material or process context - they may need to be reassessed
Show answer

D) Whether the methods and assays used to characterize and qualify the material remain valid for the changed material or process context - they may need to be reassessed

Rationale: Andrew and John specify: 'when changes are made, the methods/assays may need to be reassessed' to ensure the qualification approach remains valid for the changed material or manufacturing context.

Q47. A user asks a supplier for their performance assay results. The supplier provides numbers but no assay details. Why is this a problem under ISO 20399?

  1. It is not a problem - numbers are sufficient for performance assessment
  2. It is only a problem if the user is in Phase 3 or commercial manufacturing
  3. Without adequate assay details, the user cannot determine whether the performance data generated is applicable to their specific intended use - the supplier must provide enough information to make this assessment possible
  4. It is only a problem if the assay method is not compendial
Show answer

C) Without adequate assay details, the user cannot determine whether the performance data generated is applicable to their specific intended use - the supplier must provide enough information to make this assessment possible

Rationale: Andrew and John state: 'ancillary materials suppliers should provide adequate details of the assay to assess whether the performance data generated from the assay is applicable to their intended use.' Data without context cannot be evaluated.

Q48. Why is endotoxin highlighted as an example of a high-priority critical material attribute (CMA)?

  1. Because endotoxin is easy to test for and therefore makes a convenient example
  2. Because endotoxin has a direct and large potential impact on the safety CQA of the final drug product - a material with unacceptable endotoxin levels can cause serious harm to patients
  3. Because endotoxin is the only CMA specifically mentioned in FDA guidance for cell therapies
  4. Because endotoxin testing is the least expensive test and should always be prioritized to reduce qualification costs
Show answer

B) Because endotoxin has a direct and large potential impact on the safety CQA of the final drug product - a material with unacceptable endotoxin levels can cause serious harm to patients

Rationale: Andrew and John use endotoxin as the example of a high-priority CMA because it has 'a very large impact on the final product' safety CQA - risk ranking places high-impact safety attributes at the top of qualification priorities.

JOIN THE SCB MAILING LIST TO RECEIVE NEWS AND UPDATES

By signing up, you’re agreeing to receive email from SCB. But rest assured: we respect your privacy.